M&T Bank Corp Has $17.70 Million Stake in Elevance Health, Inc. $ELV

Key Points

• M&T Bank Corp increased its stake in Elevance Health by 160.4% in Q4, acquiring an additional 31,101 shares to hold 50,486 shares worth about $17.70 million.
• Elevance beat Q1 expectations with EPS of $12.58 (vs. $10.74 estimate) and $49.49B in revenue, raised its FY‑2026 adjusted EPS outlook to at least $26.75 and is targeting 12%+ EPS growth for 2027, prompting analyst target upgrades and a ~5.5% stock gain.
• An investor law‑firm investigation (Kirby McInerney LLP) into potential securities claims was announced, posing a legal and PR overhang that could add volatility or liability risk.

M&T Bank Corp boosted its holdings in shares of Elevance Health, Inc. (NYSE:ELV - Free Report) by 160.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 50,486 shares of the company's stock after acquiring an additional 31,101 shares during the quarter. M&T Bank Corp's holdings in Elevance Health were worth $17,698,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Salomon & Ludwin LLC boosted its position in Elevance Health by 15.7% during the 4th quarter. Salomon & Ludwin LLC now owns 265 shares of the company's stock worth $96,000 after acquiring an additional 36 shares during the period. Evergreen Capital Management LLC boosted its position in Elevance Health by 14.2% during the 4th quarter. Evergreen Capital Management LLC now owns 1,108 shares of the company's stock worth $388,000 after acquiring an additional 138 shares during the period. Revisor Wealth Management LLC boosted its position in Elevance Health by 86.6% during the 4th quarter. Revisor Wealth Management LLC now owns 1,528 shares of the company's stock worth $554,000 after acquiring an additional 709 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Elevance Health by 62.2% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 164,040 shares of the company's stock worth $57,504,000 after acquiring an additional 62,878 shares during the period. Finally, Krilogy Financial LLC boosted its position in Elevance Health by 36.2% during the 4th quarter. Krilogy Financial LLC now owns 2,471 shares of the company's stock worth $931,000 after acquiring an additional 657 shares during the period. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q1 results beat expectations — EPS of $12.58 and revenue of $49.49B topped estimates, driven in part by higher net investment income and improving claims trends; management said results reflect operating discipline. Business Wire: First Quarter Results
• Positive Sentiment: Company raised full‑year adjusted EPS outlook (reports indicate at least $26.75 for 2026 and a 12%+ EPS growth target for 2027), supporting the bullish reaction. Seeking Alpha: Raises 2026 Adjusted EPS Outlook
• Positive Sentiment: Analysts/upgrades: Evercore raised its price target to $360 (signals incremental analyst confidence and near‑term upside). MarketScreener: Evercore Raises PT
• Positive Sentiment: Dividend maintained/declared (quarterly dividend $1.72) — supports income investors and signals board confidence in cash flow.
• Neutral Sentiment: Margin expansion/efficiency story cited (AI integration and cost control noted in deep‑dive coverage) — positive long‑term but execution dependent. MSN: Q1 Deep Dive on Margin Expansion
• Neutral Sentiment: Some analyst divergence: Robert W. Baird raised its target to $331 but kept a "neutral" rating (implies limited upside from current levels). Benzinga/The Fly: Baird Update
• Negative Sentiment: Investor alert / law‑firm investigation (Kirby McInerney LLP) into potential securities claims was announced — creates legal/PR overhang and potential liability risk. Globe Newswire: Investor Alert
• Negative Sentiment: Guidance / model uncertainty: some published notes reference guidance that initially appeared below Street expectations (creates potential for revisions to analyst models and added volatility).

Elevance Health Stock Up 5.5%

Shares of Elevance Health stock opened at $346.15 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.54. Elevance Health, Inc. has a 52-week low of $273.71 and a 52-week high of $429.25. The stock has a 50-day simple moving average of $309.00 and a 200-day simple moving average of $331.66. The firm has a market cap of $76.04 billion, a price-to-earnings ratio of 14.72, a P/E/G ratio of 1.83 and a beta of 0.49.

Elevance Health (NYSE:ELV - Get Free Report) last released its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.74 by $1.84. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The business had revenue of $49.49 billion during the quarter, compared to analyst estimates of $48.21 billion. During the same quarter in the previous year, the business earned $11.97 EPS. Elevance Health's quarterly revenue was up 1.5% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, equities research analysts expect that Elevance Health, Inc. will post 25.5 earnings per share for the current fiscal year.

Elevance Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be paid a $1.72 dividend. This represents a $6.88 annualized dividend and a dividend yield of 2.0%. The ex-dividend date of this dividend is Wednesday, June 10th. Elevance Health's payout ratio is presently 27.39%.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Evercore lifted their target price on shares of Elevance Health from $345.00 to $360.00 in a research note on Thursday. Jefferies Financial Group decreased their target price on shares of Elevance Health from $395.00 to $391.00 and set a "buy" rating for the company in a research note on Monday. Leerink Partners set a $364.00 target price on shares of Elevance Health in a research note on Thursday. Mizuho decreased their target price on shares of Elevance Health from $413.00 to $350.00 and set an "outperform" rating for the company in a research note on Wednesday, March 11th. Finally, Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and set a $332.00 price target on shares of Elevance Health in a report on Thursday, January 29th. Eleven analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $380.10.

Elevance Health Company Profile

Elevance Health, Inc NYSE: ELV is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company's strategic focus on integrated health care and benefit delivery.

Elevance's core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.